COMMON WARTS (VERRUCA VULGARIS)
Clinical trials for COMMON WARTS (VERRUCA VULGARIS) explained in plain language.
Never miss a new study
Get alerted when new COMMON WARTS (VERRUCA VULGARIS) trials appear
Sign up with your email to follow new studies for COMMON WARTS (VERRUCA VULGARIS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stubborn warts: extended treatment shows promise
Disease control Recruiting nowThis study follows people who already took part in earlier YCANTH wart studies. It tests whether up to 4 more treatments, applied every 21 days, can safely clear common warts. About 600 adults and children will be monitored for a year. The goal is to see if the medicine continues…
Matched conditions: COMMON WARTS (VERRUCA VULGARIS)
Phase: PHASE3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Wart war: vitamin D3 or acyclovir injections – which works better?
Disease control Recruiting nowThis study tests whether injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts can clear them. Forty people aged 12 and older with common, plantar, flat, or nail warts will receive injections every two weeks for up to four sessions. The main goal is to se…
Matched conditions: COMMON WARTS (VERRUCA VULGARIS)
Phase: PHASE4 • Sponsor: Riphah International University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New gel could zap away common warts in just weeks
Disease control Recruiting nowThis study tests a gel called YCANTH on common warts caused by HPV. About 300 people aged 2 and older with at least one wart will apply the gel or a fake version. The goal is to see if the gel can clear all warts by day 84.
Matched conditions: COMMON WARTS (VERRUCA VULGARIS)
Phase: PHASE3 • Sponsor: Verrica Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC